Showing 47,641 - 47,660 results of 224,509 for search '(( a ((a decrease) OR (linear decrease)) ) OR ( a ((latent decrease) OR (largest decrease)) ))', query time: 1.77s Refine Results
  1. 47641
  2. 47642

    Descriptive statistics. by Amy L. MacQuarrie (18806270)

    Published 2024
    “…A sample of 147 Canadian adult participants who had attempted to decrease or quit cannabis were recruited from the community (<i>n</i> = 84, 57.14%) and crowdsourcing (<i>n =</i> 63, 42.86%). …”
  3. 47643

    Sugar-Based Gemini Surfactants with Peptide BondsSynthesis, Adsorption, Micellization, and Biodegradability by Tomokazu Yoshimura (2070670)

    Published 2005
    “…The adsorption and micellization properties of C<i><sub>n</sub></i>peLac and 2C<i><sub>n</sub></i>peLac were characterized by the measurement of their equilibrium and dynamic surface tension, steady-state fluorescence using pyrene as a probe, dynamic light scattering (DLS), and time-resolved fluorescence quenching (TRFQ), and their biodegradability was also investigated. …”
  4. 47644
  5. 47645

    XTH43-RNAi impairs <i>H</i>. <i>glycines</i> parasitism, revealed by the female index (FI). by Prakash M. Niraula (6816713)

    Published 2021
    “…<p><b>A</b>. <i>G</i>. <i>max</i> plant (left panel) prior to genetic engineering. …”
  6. 47646

    Data_Sheet_1_A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients With Rheumatoid Arthritis, Psoriasis... by Christian Dejaco (12618)

    Published 2022
    “…Mean age was 50.2 ± 14.2 years; 64% were female. Disease activity decreased from baseline to month 24 (RA: CDAI −24.3 ± 13.5; axSpA: BASDAI −4.4 ± 2.1, and PsA: CDAI −21.7 ± 8.5, p < 0.0001, each). …”
  7. 47647

    Data_Sheet_2_A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients With Rheumatoid Arthritis, Psoriasis... by Christian Dejaco (12618)

    Published 2022
    “…Mean age was 50.2 ± 14.2 years; 64% were female. Disease activity decreased from baseline to month 24 (RA: CDAI −24.3 ± 13.5; axSpA: BASDAI −4.4 ± 2.1, and PsA: CDAI −21.7 ± 8.5, p < 0.0001, each). …”
  8. 47648

    Variations of the ratio of rework and regular production rates (<i>P</i><sub>2i</sub>/<i>P</i><sub>1i</sub>) and their effects on the expected system cost E[<i>TCU</i>(<i>T*</i>, <i>n*</i>)], which shows that as <i>P</i><sub>2i</sub>/<i>P</i><sub>1i</sub> decreases below a turning point 0.5, the expected system cost begins to increase significantly by Singa Wang Chiu (3383579)

    Published 2016
    “…<p>Variations of the ratio of rework and regular production rates (<i>P</i><sub>2i</sub>/<i>P</i><sub>1i</sub>) and their effects on the expected system cost E[<i>TCU</i>(<i>T*</i>, <i>n*</i>)], which shows that as <i>P</i><sub>2i</sub>/<i>P</i><sub>1i</sub> decreases below a turning point 0.5, the expected system cost begins to increase significantly</p>…”
  9. 47649

    Contribution of the through-mask leakages from the cavity and channel network distributed along the periphery of the mask; a–c and d–f are decreasing porosity <i>c</i><sub><i>k</i></sub> = 100,500,1000 (<i>kg</i>/<i>m</i><sup>2</sup> <i>s</i>) for outward protection (with nose clips) and inward protection model, respectively; the <i>k</i><sub><i>L</i></sub> for inward protection model is 0.5. by Akshay Anand (118579)

    Published 2025
    “…<p>Contribution of the through-mask leakages from the cavity and channel network distributed along the periphery of the mask; a–c and d–f are decreasing porosity <i>c</i><sub><i>k</i></sub> = 100,500,1000 (<i>kg</i>/<i>m</i><sup>2</sup> <i>s</i>) for outward protection (with nose clips) and inward protection model, respectively; the <i>k</i><sub><i>L</i></sub> for inward protection model is 0.5.…”
  10. 47650
  11. 47651
  12. 47652

    DataSheet_1_Multi-b-values-fitting readout-segmentation of long variable echo-trains diffusion-weighted imaging (RESOLVE DWI) in evaluation of disease activity and curative effect... by Xianyuan Chen (16482096)

    Published 2023
    “…Background<p>Disease activity is relevant to the treatment and prognosis of axSpA, and methods to quantitatively assess disease activity and efficacy of axSpA are still being explored.…”
  13. 47653
  14. 47654
  15. 47655
  16. 47656
  17. 47657
  18. 47658
  19. 47659
  20. 47660